Active	Status	Sponsor type	Region	Phase	Filter
2 Active 6 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Leoni, Matthew
CVL-354-1001, NCT05138653: A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants	Completed	1	73	US	CVL-354, Placebo	Cerevel Therapeutics, LLC, National Institute on Drug Abuse (NIDA)	Healthy Participants	01/23	01/23
NCT04787302: PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing	Completed	1	15	Europe, US	CVL-231, PF-06852231	Cerevel Therapeutics, LLC	Schizophrenia	07/23	07/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Leoni, Matthew
CVL-354-1001, NCT05138653: A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants	Completed	1	73	US	CVL-354, Placebo	Cerevel Therapeutics, LLC, National Institute on Drug Abuse (NIDA)	Healthy Participants	01/23	01/23
NCT04787302: PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing	Completed	1	15	Europe, US	CVL-231, PF-06852231	Cerevel Therapeutics, LLC	Schizophrenia	07/23	07/23